Relay Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Relay Therapeutics Inc RLAY.OQ reported a quarterly adjusted loss of 46 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -62 cents. The mean expectation of eleven analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -60 cents to -31 cents per share.

• Revenue fell 23.3% to $7.68 million from a year ago; analysts expected $10.00 thousand.

• Relay Therapeutics Inc's reported EPS for the quarter was a loss of 46 cents​.

• The company reported a quarterly loss of $77.07 million.

• Relay Therapeutics Inc shares had risen by 24.0% this quarter and lost 21.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 18.9% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Relay Therapeutics Inc is $16.50

This summary was machine generated from LSEG data May 5 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)